Can paxlovid hold the line against severe COVID-19 outside the lab?
NCT ID NCT05890612
First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time
Summary
This study watches how Paxlovid performs in real life, not in a controlled trial. It follows about 3,000 people in Korea with mild-to-moderate COVID-19 who are at high risk of getting very sick. Researchers track side effects, hospitalizations, and deaths over 28 days after the last dose to see if the antiviral works as expected in routine care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Paxlovid (nirmatrelvir/ritonavir), an antiviral medication
- What this could lead to
- If successful, this could confirm that Paxlovid works well and is safe in everyday use for people at high risk of severe COVID-19, supporting its wider use.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by other factors. Side effects are still possible, and the findings may not apply to all populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer Korea
RECRUITINGSeoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can a quick online game train people to spot COVID-19 lies?